Skip to main content

The Wistar Institute and Batavia Biosciences Launch Collaboration to Manufacture and Distribute Wistar’s Rubella Vaccine Globally

PHILADELPHIA — (April 29, 2020) — The Wistar Institute and Batavia Biosciences announce the launch of a strategic collaboration aimed to streamline the clinical grade manufacture and global distribution of Wistar’s rubella vaccine seed stock commonly known as RA 27/3. In December 2019, Wistar was awarded a $1M grant from the Bill & Melinda Gates Foundation to support this global access-focused international collaboration.

“We must continually find creative ways for non-profit and for-profit companies to work together to make life-saving technologies easily accessible to people around the globe,” said Heather Steinman, Ph.D., MBA, Wistar’s vice president for business development and executive director of technology transfer. “The generous funding support from the Gates Foundation is the glue that has enabled Wistar and Batavia Biosciences to unite with a single mission of ensuring long term supplies of RA 27/3”.

“Combining the established know-how and experience at The Wistar Institute with our technology to manufacture vaccines at low cost and the support of the Bill & Melinda Gates Foundation provides us with an exciting opportunity to increase the distribution of a critical vaccine”, said Chris Yallop, Ph.D., Batavia’s CSO and COO.

Rubella is a contagious viral disease that mainly affects children and young adults, typically manifested with mild clinical symptoms. However, rubella infection during pregnancy, especially during the first trimester, can result in severe complications including miscarriage, fetal death, stillbirth, and congenital malformations, known altogether as congenital rubella syndrome (CRS).

The rubella vaccine was developed at Wistar in 1969 in the laboratory of Stanley A. Plotkin, M.D. The vaccine is safe and effective at providing long-lasting protection. The number of countries using rubella vaccines in their national immunization programs is steadily increasing, and global rubella vaccine coverage in 2018 was estimated at 69% by the World Health Organization. Despite this progress, rubella control is lagging behind, and several countries have neither introduced the vaccine nor set elimination or control targets.

One major issue is supply shortage, mainly due to insufficient production capability. The number of companies that produce rubella vaccines has been steadily decreasing, causing global shortages of the vaccine.

Batavia shares with Wistar a focus on rapidly accelerating the development of vaccines and other biopharmaceutical product candidates from discovery to market to improve global health. This collaboration with the Netherlands-based company bolsters the developing relationship between geographies as Wistar also recently announced the establishment of the Wistar-Schoemaker International Postdoctoral Fellowship with the Leiden University Medical Center in the Netherlands (LUMC), which will bring recent Ph.D. graduates trained at LUMC to Wistar to advance their research education under the mentorship of cutting-edge biomedical research leaders.

Thanks to support from the Bill & Melinda Gates Foundation, Wistar will be able to archive the existing supplies of research-grade rubella virus seed stock and transfer the necessary supplies to Batavia, to enable the development of readily accessible good manufacturing practice (GMP)-grade rubella drug substances and drug product formulations, with the intent to distribute these critical materials to vaccine manufacturers around the world through a universal license agreement construct.


The Wistar Institute is an international leader in biomedical research with special expertise in cancer research and vaccine development. Founded in 1892 as the first independent nonprofit biomedical research institute in the United States, Wistar has held the prestigious Cancer Center designation from the National Cancer Institute since 1972. The Institute works actively to ensure that research advances move from the laboratory to the clinic as quickly as possible. Wistar’s Business Development team is dedicated to advancing Wistar Science and Technology Development through creative collaborations.

Batavia Biosciences significantly contributes to ease human suffering from infectious diseases and cancer by improving the success rate in the translation of candidate medicines from discovery to the clinic. We offer our innovative technologies and in-depth know-how in order to help our partners to complete preclinical phases in biopharmaceutical product development at higher speed, reduced costs and increased success. The company focuses on the early stages of product development including cell line generation, upstream process development, purification development, product characterization and clinical manufacturing. Headquartered in Leiden, the Netherlands, with a subsidiary in Woburn, Massachusetts, and offices in Hong Kong, Batavia Biosciences is privileged to have strong strategic partners worldwide. For more information visit

For press inquiries or more information please contact